MigraineMind research summary
Lidocaine Combined With Platelet-Rich Plasma for Stellate Ganglion Block in Chronic Migraine: A Multicenter, Prospective, Propensity Score-Matched Cohort Study.
Brain Behav | 2026
Clinical trialSummary
This study looked at a new treatment for chronic migraine. It compared two methods: one using lidocaine alone and the other using lidocaine with platelet-rich plasma (PRP). Researchers enrolled 200 adults with chronic migraines across three hospitals. Participants chose their treatment, with 100 receiving each method. They measured changes in headache days one month after treatment. Other factors included headache frequency, pain intensity, and overall well-being. After matching groups for fairness, they analyzed results from 66 patients in each group. The results showed that the combination of PRP and lidocaine might provide better relief than lidocaine alone. This suggests that adding PRP could improve treatment outcomes for people suffering from chronic migraines. Overall, this research highlights a potential new approach to managing chronic migraine pain effectively. Clinical relevance: This study suggests that combining platelet-rich plasma with lidocaine may enhance migraine treatment effectiveness, offering hope for improved management strategies for chronic migraine patients.
Key Learning Points
- A new treatment for chronic migraine combines lidocaine with platelet-rich plasma, which may offer better relief than lidocaine alone.
- Patients with chronic migraines can choose their preferred treatment method in this study.
- The study involved 200 adults and measured changes in headache days and overall well-being after treatment.
- Results indicate that adding platelet-rich plasma could improve outcomes for chronic migraine sufferers.
- This research presents a promising approach to enhance the management of chronic migraine pain.
Research Informatics
NON-RANDOMISED CLINICAL TRIAL
PRP plus lidocaine improved migraine outcomes over lidocaine alone.
safetyNo significant differences in safety outcomes
follow Up1 month
conditionChronic migraine
populationAdults with chronic migraine
sample Size132
primary OutcomeMean change in monthly headache days
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.